ABPI and our regional industry groups - andy riley
1. ABPI and our Regional
Industry Groups
Andy Riley, Partnerships Manager, Midlands and East
2.
3. Real world data and e-health
ABPI landscape and policy map
Innovation, Health
and Wealth
value
based
pricing
PPRS
Commissioning
Reputation
UK Competitiveness
NHS Partnerships
Discovery Development Approval Fair Price Access Uptake Patients
Supply Chain
Partnerships for research
Animal research
EU Influence
Clinical research
Regulatory framework and MHRA
Manufacturing and the environment
Schools, higher education and skills
Intellectual property and patent
Pharmacovigilance
Patient Group Forum
Medicines Optimisation
HTA
4. Our partnerships for delivery
•We have an MOU with the NHS Confederation, ABHI and Medilinks to
support the implementation of Innovation, Health and Wealth
http://www.nhsconfed.org/priorities/latestnews/Pages/NHS-Confederation-
joins-ABPI-ABHI-innovation-project.aspx
•This strategic agreement aims to increase the adoption and diffusion of
proven technologies in areas of high clinical need to deliver high quality
patient outcome and efficiency gains
•It includes showcasing best practice for joint working, judged by an
independent panel – our first launch event was in February
•We work on policy at a national level with a range of organisations,
including the DoH, NHS England, NICE, Royal Colleges and others
5. Our vision
NHS Partnerships Team established in 2012,
led by Carol Blount, our director:
– Kevin Blakemore, National Manager
– Regional Managers:
– Di Vegh (South)
– Harriet Lewis (North)
– Andy Riley (Mids and East)
– Karen Thomas (London)
– Mike Ringe, Therapy Group Manager
– Terry Harrison, consultant
– Industry secondee
currently Farid Bidgoli from AZ
Industry as an integral part of the NHS’s solution
to the delivery of better patient outcomes
6. NHS Partnership team priorities
We are:
- Identifying and sharing local NHS issues, organisational and policy changes with member
companies
- Taking the lead on themes from the Innovation, Health and Wealth and other key priorities,
e.g. medicines optimisation
- Demonstrating the value of medicines as an opportunity to improve outcomes rather than as
a cost pressure to commissioners and providers
- Supporting companies in the development of Joint Working projects
We aren’t:
- Promoting a particular company/ therapy area or product
- Trying to improve your market share
- Replicating or ‘competing’ with member company field teams
- The only way that the NHS can engage with pharma
Notas del editor
A full service trade association supporting all research-based biopharmaceutical companiesRecognised by UK&I Governments as the body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirementsWork across the UK – head offices in London, Edinburgh, Cardiff, Belfast – and a field team in EnglandMember companies represent 90% of the value of all medicines used by the NHSCollaborate with the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on EU issues via Brussels and GenevaThe arms length body of the Prescription Medicines Code of Practice Authority (PMCPA) upholds the ABPI Code of Conduct
ABPIS managing issues where companies can’tA lot of which facilitates what goes on in the previous slidesCreates an environment which ensures the previous channels are openIssues that matter to comapnies and how ABPICompanies can’t address the issues in the same way as ABPI....